ANXA1 and inflammatory bowel disease: Still, despite there being discrepancies, certain AnxA1 roles described in murine models of experimental colitis are corroborated in human IBD patients, such as infliximab treatment in AnxA1 knockout mice undergoing DSS colitis failing to attenuate disease progression, which links to other findings evidencing infliximab-responsive IBD patients show a greater expression of AnxA1 in colon tissue (Sena et al., 2013; de Paula-Silva et al., 2016).